The impact of prostate volume changes during external-beam irradiation in consequence of HDR brachytherapy in prostate cancer treatment

Herrmann, Markus K. A.; Gsänger, Tammo; Strauß, Arne; Kertesz, Tereza; Wolff, Hendrik A.; Christiansen, Hans; Vorwerk, Hilke; Hess, Clemens F.; Hille, Andrea

doi:10.1007/s00066-009-1942-7

Cited by 5 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The quantity of needles used for the HDR-brachytherapy was in minimum 14 and 15, in maximum 18 and 17 and in mean 16 and 17, respectively. We both observed an increase (14 patients), a decrease (2 patients) and no change (2 patients) in prostate volumes after HDR-brachytherapy including application of the gold markers, as it has previously been published by our department [27]. In the analyzed 18 patients no correlation was seen between the volume change of prostate and magnitude of seed gold marker displacement.…”

Section: Discussionsupporting

confidence: 72%

Gold marker displacement due to needle insertion during HDR-brachytherapy for treatment of prostate cancer: A prospective cone beam computed tomography and kilovoltage on-board imaging (kV-OBI) study

et al. 2012

Self Cite

View full text Add to dashboard Cite

PurposeTo evaluate gold marker displacement due to needle insertion during HDR-brachytherapy for therapy of prostate cancer.Patients and methods18 patients entered into this prospective evaluation. Three gold markers were implanted into the prostate during the first HDR-brachytherapy procedure after the irradiation was administered. Three days after marker implantation all patients had a CT-scan for planning purpose of the percutaneous irradiation. Marker localization was defined on the digitally-reconstructed-radiographs (DRR) for daily (VMAT technique) or weekly (IMRT) set-up error correction. Percutaneous therapy started one week after first HDR-brachytherapy. After the second HDR-brachytherapy, two weeks after first HDR-brachtherapy, a cone-beam CT-scan was done to evaluate marker displacement due to needle insertion. In case of marker displacement, the actual positions of the gold markers were adjusted on the DRR.ResultsThe value of the gold marker displacement due to the second HDR-brachytherapy was analyzed in all patients and for each gold marker by comparison of the marker positions in the prostate after soft tissue registration of the prostate of the CT-scans prior the first and second HDR-brachytherapy. The maximum deviation was 5 mm, 7 mm and 12 mm for the anterior-posterior, lateral and superior-inferior direction. At least one marker in each patient showed a significant displacement and therefore new marker positions were adjusted on the DRRs for the ongoing percutaneous therapy.ConclusionsNeedle insertion in the prostate due to HDR-brachytherapy can lead to gold marker displacements. Therefore, it is necessary to verify the actual position of markers after the second HDR-brachytherapy. In case of significant deviations, a new DRR with the adjusted marker positions should be generated for precise positioning during the ongoing percutaneous irradiation.

show abstract

Section: Discussionsupporting

confidence: 72%

Gold marker displacement due to needle insertion during HDR-brachytherapy for treatment of prostate cancer: A prospective cone beam computed tomography and kilovoltage on-board imaging (kV-OBI) study

et al. 2012

Self Cite

View full text Add to dashboard Cite

show abstract

“…HDR-BT boost has been accepted as a standard technique for dose escalation in the curative treatment of localized prostate cancer [9,15,16,21,25,28,33,44,46]. Recently, several phase I/II studies have been initiated to test the feasibility of HDR-BT as a monotherapy [29,51].…”

Section: Discussionmentioning

confidence: 99%

Dosimetric Evaluation of High-Dose-Rate Interstitial Brachytherapy Boost Treatments for Localized Prostate Cancer

et al. 2010

View full text Add to dashboard Cite

US-based treatment plans for HDR prostate implants based on the real positions of catheters provided acceptable dose distributions. In the majority of the cases, the doses to urethra and rectum were kept below the defined tolerance levels. For rectum, the dose in reference points correlated well with dose-volume parameters. For urethra dose characterization, the use of D1 volumetric parameter is recommended.

show abstract

“…22 High-dose rate brachytherapy may also change prostate size. 12 Although many patients have shown decreased prostate size after IMRT, some of them were treated with a combination of ADT. The hormonal therapy might mask the effect of size reduction by IMRT.…”

Section: Discussionmentioning

confidence: 99%

Does intensity-modulated radiation therapy (IMRT) alter prostate size? Magnetic resonance imaging evaluation of patients undergoing IMRT alone

Tanaka

Yamaguchi

Hachiya

et al. 2017

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

The impact of prostate volume changes during external-beam irradiation in consequence of HDR brachytherapy in prostate cancer treatment

Cited by 5 publications

References 38 publications

Gold marker displacement due to needle insertion during HDR-brachytherapy for treatment of prostate cancer: A prospective cone beam computed tomography and kilovoltage on-board imaging (kV-OBI) study

Gold marker displacement due to needle insertion during HDR-brachytherapy for treatment of prostate cancer: A prospective cone beam computed tomography and kilovoltage on-board imaging (kV-OBI) study

Dosimetric Evaluation of High-Dose-Rate Interstitial Brachytherapy Boost Treatments for Localized Prostate Cancer

Does intensity-modulated radiation therapy (IMRT) alter prostate size? Magnetic resonance imaging evaluation of patients undergoing IMRT alone

Contact Info

Product

Resources

About